VYNE Therapeutics’ (VYNE) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of VYNE Therapeutics (NASDAQ:VYNE) in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $5.75 price objective on the stock.

Separately, BTIG Research began coverage on shares of VYNE Therapeutics in a research report on Monday, November 18th. They set a “buy” rating and a $8.00 target price on the stock.

VYNE Therapeutics Trading Up 1.5 %

Shares of VYNE stock opened at $2.74 on Wednesday. VYNE Therapeutics has a 1 year low of $1.57 and a 1 year high of $4.30. The firm’s fifty day simple moving average is $2.82 and its 200 day simple moving average is $2.46. The firm has a market capitalization of $40.42 million, a P/E ratio of -3.19 and a beta of 1.28.

Insiders Place Their Bets

In other VYNE Therapeutics news, Director Patrick G. Lepore purchased 15,000 shares of the firm’s stock in a transaction on Wednesday, January 15th. The shares were purchased at an average price of $2.92 per share, for a total transaction of $43,800.00. Following the completion of the purchase, the director now directly owns 51,472 shares of the company’s stock, valued at approximately $150,298.24. This represents a 41.13 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 4.80% of the company’s stock.

Institutional Investors Weigh In On VYNE Therapeutics

A number of institutional investors have recently bought and sold shares of the business. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in VYNE Therapeutics during the fourth quarter worth $823,000. Bridgeway Capital Management LLC acquired a new stake in shares of VYNE Therapeutics in the 4th quarter valued at $124,000. Acorn Capital Advisors LLC acquired a new stake in shares of VYNE Therapeutics in the 4th quarter valued at $1,531,000. Jane Street Group LLC acquired a new stake in shares of VYNE Therapeutics in the 4th quarter valued at $68,000. Finally, Schonfeld Strategic Advisors LLC boosted its stake in shares of VYNE Therapeutics by 4.8% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 176,658 shares of the company’s stock valued at $592,000 after purchasing an additional 8,058 shares in the last quarter. Institutional investors and hedge funds own 83.78% of the company’s stock.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.